Pituitary neuroendocrine tumors treated with stereotactic radiosurgery
Journal of Neuro-Oncology · 2025
DOI: 10.1007/s11060-024-04864-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Neuro-Oncology, 2025. Verfasst von Inhwa Kim und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, University of Toronto, Toronto, ON, Canada. Hauptthemen laut MEDLINE: Radiosurgery, Pituitary Neoplasms, Neuroendocrine Tumors. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Purpose
Pituitary neuroendocrine tumors (pitNETs) are benign tumors that may recur after surgical resection or persist following medical management. The objective of this study was to evaluate outcomes and toxicities of patients with pitNETs treated with stereotactic radiosurgery (SRS) at a single institution.
Methods
We completed a retrospective, single-institution study of patients with pitNETs treated with frame-based, single-fraction, cobalt-60 SRS between September 2005 and June 2023. The primary endpoint was local tumor control. Secondary endpoints included endocrine control (for functional tumors), overall survival, and toxicities.
Results
A total of 88 lesions in 83 patients were treated with SRS. Most lesions (70%) were non-functional tumors. Of the 26 functioning tumors, 6 patients achieved endocrine remission with SRS alone (23%), and the remainder achieved remission with combined medical management. With a median patient follow-up of 4.7 years, no local tumor recurrences were observed with an estimated local control probability of 100%. Two- and five-year overall survival estimates were 97% (95% confidence interval [CI] 89–99) and 95% (95% CI 84–98), respectively. Causes of death were unrelated to PitNET or SRS. Twelve patients (14%) developed hypopituitarism after SRS. Despite the 34 lesions that were ≤ 3 mm from optic structures, no patients developed any optic neuropathy or visual decline post SRS.
Conclusions
SRS is a highly effective modality for recurrent or residual pitNETs. This study observed a local control of 100% with no cases of optic toxicities after a median follow-up of 4.7 years. These observed findings suggest that dose de-escalation may be possible for future treatment of pitNETs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology, University of Toronto, Toronto, ON, Canada.
- Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
- Division of Neurosurgery, Toronto Western Hospital, University Health Network, Toronto, ON, Canada.
- Division of Neurosurgery, St. Michael's Hospital, Unity Health Toronto, Toronto, ON, Canada.
- Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada. derek.tsang@uhn.ca.
Zitieren
APA
Kim, I., Yan, M., Sourour, M., Heaton, R., Faulkner, C., Kalyvas, A., Keilty, D. M., Cusimano, M. D., Payne, D., Laperriere, N., Shultz, D. B., Alli, S. B., Zadeh, G., & Tsang, D. S. (2025). Pituitary neuroendocrine tumors treated with stereotactic radiosurgery. Journal of Neuro-Oncology. https://doi.org/10.1007/s11060-024-04864-3
Vancouver
Kim I, Yan M, Sourour M, Heaton R, Faulkner C, Kalyvas A, et al. Pituitary neuroendocrine tumors treated with stereotactic radiosurgery. Journal of Neuro-Oncology. 2025. doi:10.1007/s11060-024-04864-3
BibTeX
@article{Kim2025,
author = {Kim, Inhwa and Yan, Michael and Sourour, Michel and Heaton, Robert and Faulkner, Colin and Kalyvas, Aristotelis and Keilty, Dana M and Cusimano, Michael D and Payne, David and Laperriere, Normand and Shultz, David B and Alli, Saira B and Zadeh, Gelareh and Tsang, Derek S},
title = {Pituitary neuroendocrine tumors treated with stereotactic radiosurgery},
journal = {Journal of Neuro-Oncology},
year = {2025},
doi = {10.1007/s11060-024-04864-3}
}
EUVIMED